Clinical Aspects of Ankylosing Spondylitis

Ankylosing Spondylitis: Diagnosis and Management

Volumn , Issue , 2006, Pages 45-70

  Irene E van der, Horst Bruinsma ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70349338462     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849374463-3     Document Type: Chapter

References (158)

1. Zeidler H, Schumacher HR. Spondylarthropathies. Baillieres Clin Rheumatol 1998; 12(4):551-583, 695-715.
2. Calin A, Taurog JD. The Spondylarthritides. Oxford: Oxford University Press, 1998.
3. van der Linden S, Valkenburg HA, Cats A. Evaluation of the diagnostic criteria for ankylosing spondylitis; a proposal for the modification of the New York criteria. Arthritis Rheum 1984; 27:361-368.
4. Gran JT, Husby G, Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985; 44:359-367.
5. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67.
6. Dougados M, van der Linden S, Juhlin R, et al. The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.
7. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis. The role of genes, HLA and the environment. Arthritis Rheum 1997; 40:1823-1828.
8. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27(3):241-249.
9. Laval SH, Timms A, Edwards S, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001; 68(4): 918-926.
10. van der Paardt M, van der Horst-Bruinsma IE, Crusius JBA, et al. Interleukin-1 beta and interleukin-1 receptor antagonist gene polymorphisms in the susceptibility to ankylosing spondylitis. Rheumatology 2002; 41:1419-1423.
11. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411(6837):599-603.
12. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411(6837):603-606.
13. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357(9272):1925-1928.
14. van der Paardt M, Crusius JBA, de Koning MHMT, et al. CARD 15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003; 4:77-78.
15. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6:597-641.
16. van der Paardt M, Crusius JBA, Garcia-Gonzalez MA, Dijkmans BAC, Pena AS, van der Horst-Bruinsma IE. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor B1 gene polymorphisms. Ann Rheum Dis 2005; 64(4):616-619.
17. Koehler L, Zeidler H, Hudson AP. Aetiological agents: their molecular biology and phagocyte-host interaction. Baillieres Clin Rheumatol 1998; 12(4):589-609.
18. Lange U, Berliner M, Weidner W, Schiefer HG, Schmidt KL, Federlin K. Ankylosing spondylitis and urogenital infection: diagnosis of urologic infection and correlation with rheumatologic findings. Z Rheumatol 1996; 55(4):249-255.
19. van der Paardt M, van Denderen JC, van den Brule AJC, et al. Prevalence of Chlamydia trachomatis in urine of male patients with ankylosing spondylitis is not increased. Ann Rheum Dis 2000; 59:300-303.
20. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 2001; 28:2283-2288.
21. Feldtkeller E. Age at disease onset and delayed diagnosis of spondylarthropathies. Z Rheumatol 1999; 58:21-30.
22. Burgos-Vargas R, Vazquez-Mellado J. The early clinical recognition of juvenile onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38:835-844.
23. Calin A, Fries JF. Striking prevalence of ankylosing spondylitis in ‘‘healthy’’ w27 positive males and females. A controlled study. N Engl J Med 1975; 293:835-839.
24. Will R, Edmunds L, Elswood J, Calin A, et al. Is there a sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol 1990; 17:1649-1652.
25. Gran JT, Ostensen M, Husby G, et al. A clinical comparison between males and females with ankylosing spondylitis. J Rheumatol 1985; 12:126-129.
26. Braunstein EM, Martel W, Moidel R. Ankylosing spondylitis in men and women: a clinical and radiographic comparison. Radiology 1982; 144:91-94.
27. Jiminez-Balderas F, Mintz G. Ankylosing spondylitis: a clinical course in women and men. J Rheumatol 1993; 20:2069-2072.
28. Resnick D, Niwayama G. Ankylosing Spondylitis. In: Resnick D, ed. Diagnosis of bone and joint disorders. 3rd edition. Philadelphia: WB Saunders; 1995:1008-1074.
29. Ostensen M, Fuhrer L, Mathieu R, et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004; 63:1212-1217.
30. Ostensen M, Ostensen H. Ankylosing spondylitis—the female aspect. J Rheumatol 1998; 25(1):120-124.
31. Ostensen M. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. Am J Reprod Immunol 1992; 28:235-237.
32. Ostensen M, Romberg O, Husby G. Ankylosing spondylitis and motherhood. Arthritis Rheum 1982; 25(2):140-143.
33. Ostensen M, Fuhrer L, Mathieu R, Seitz M, Villiger PM. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004; 63(10):1212-1217.
34. Oostveen J, Prevo R, den Boer J, et al. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol 1999; 26:1953-1958.
35. Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37:1039-1045.
36. Khan MA. Ankylosing spondylitis: clinical aspects. In: Calin A, Taurog J, eds. The Spondylarthritides. Oxford: Oxford University Press, 1998.
37. Ramos-Remus C, Gomez-Vargas A, Guzman-Guzman JL, et al. Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis. J Rheumatol 1995; 22:2120.
38. Thompson GH, Khan MA, Bilenker RM, et al. Spontaneous atlantoaxial subluxation as presenting manifestation of juvenile ankylosing spondylitis. Spine 1982; 7:78-79.
39. Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patient with early, active ankylosing spondylitis: follow up study. Arthritis Rheum 1999; 42(11):2319-2324.
40. Toussirot E, Michel F, Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 2001; 40(8):882-888.
41. Bessant R, Keat A. How should clinicians manage osteoporosis in ankylosing spondylitis? J Rheumatol 2002; 29:1511-1519.
42. Dos Santos FP, Constantin A, Laroche M, et al. Whole body and regional bone mineral density in ankylosing spondylitis. J Rheumatol 2001; 28(3):547-549.
43. Singh A, Bronson W, Walker SE, Allen SH. Relative value of femoral and lumbar bone mineral density assessments in patients with ankylosing spondylitis. South Med J 1995; 88(9):939-943.
44. Juanola X, Mateo L, Nolla JM, Roig-Vilaseca D, Campoy E, Roig-Escofet D. Bone mineral density in women with ankylosing spondylitis. J Rheumatol 2000; 27:1028-1031.
45. Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002; 29(3):516-521.
46. Mitra D, Elvins DM, Speden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology (Oxford) 2000; 39(1):85-89.
47. Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV, Spector TD. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994; 53(2):117-121.
48. Ralston SH, Urquhart GD, Brzeski M, Sturrock RD. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 1990; 300(6724): 563-565.
49. Nakstad PH, Server A, Josefsen R. Traumatic cervical injuries in ankylosing spondylitis. Acta Radiol 2004; 45:222-226.
50. Rasker JJ, Prevo RL, Lanting PJH. Spondylodiscitis in ankylosing spondylitis, inflammation or trauma? Scand J Rheumatol 1996; 25:52-57.
51. Dihlmann W, Delling G. Disco-vertebral destructive lesions (so-called Andersson lesions) associated with ankylosing spondylitis. Skeletal Radiol 1978; 3:10-16.
52. Kabaskal Y, Garrett SL, Calin A, et al. The epidemiology of spondylodiscitis in ankylosing spondylitis, a controlled study. Br J Rheum 1996; 35:660-663.
53. Resnick D, Niwayama G. Ankylosing spondylitis. In: Resnick D, ed. Diagnosis of Bone and Joint Disorders. 3rd ed. Philadelphia, PA: WB Saunders, 1995:1008-1074.
54. McGonagle D, Khan MA, Marzo-Ortega H, et al. Enthesitis in ankylosing spondylitis and related spondylarthropathies. Curr Opin Rheumatol 1999; 11:244-250.
55. Heuft-Dorenbosch L, Spoorenberg A, Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127-132.
56. Linder R, Hoffmann A, Brunner R. Prevalence of the spondyloarthritides in patients with uveitis. J Rheumatol 2004; 31(11):2226-2229.
57. Monnet D, Breban M, Hudry C, Dougados M, Brezin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004; 111(4):802-809.
58. Pato E, Banares A, Jover JA, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000; 27(9):2198-2202.
59. Linssen A, Rothova A, Valkenburg HA, et al. The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Invest Ophthalmol Vis Sci 1991; 32(9):2568-2578.
60. Kruithof E, Kestelyn P, Elewaut C, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis 2002; 61(5):470.
61. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002; 109(12):2342-2346.
62. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004; 111(2):352-356.
63. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003; 121(4):437-440.
64. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003; 87(7):925.
65. Rosenbaum JT. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004; 50(11):3736-3737.
66. Mielants H, Veys EM, Cuvelier C, De Vos M. Ileocolonoscopy and spondarthritis. Br J Rheumatol 2003; 27(2):163-164.
67. De Keyser F, Mielants H. The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surface. J Rheumatol 2003; 30(11):2306-2307.
68. Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic, and genetic features in relation to the type of histology. A prospective study. J Rheumatol 1991; 18(10): 1542-1551.
69. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22(12):2273-2278.
70. Youssef W, Russell AS. Cardiac, ocular, and renal manifestations of seronegative spondyloarthropathies. Curr Opin Rheumatol 1990; 2:582-585.
71. O’Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis 1992; 51:705-706.
72. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BAC, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthr Rheum 2004; 34:585-592.
73. Brewerton DA, Goddard DH, Moore RB, et al. The myocardium in ankylosing spondylitis: a Clinical, echocardiographic, and histopathological study. Lancet 1987; 1(8540): 995-998.
74. Gould BA, Turner J, Keeling DH, et al. Myocardial dysfunction in ankylosing spondylitis. Ann Rheum Dis 1992; 51:227-232.
75. Nagyhegyi G, Nadas I, Banyai F, et al. Cardiac and cardiopulmonary disorders in patients with ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 1988; 6:17-26.
76. Roberts MET, Wright V, Hill AGS, Mehra AC. Psoriatic arthritis: follow-up study. Ann Rheum Dis 1976; 35:206-212.
77. O’Neill TW, King G, Graham IM. Echocardiographic abnormalities in ankylosing spondylitis. Ann Rheum Dis 1992; 51:652-654.
78. Qaiyumi S, Hassan ZU, Toone E. Seronegative spondyoarthropathies in lone aortic insufficiency. Arch Intern Med 1985; 145:822-824.
79. Bergfeldt L, Edhag O, Vedin L, et al. Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system: prevalence among 223 pacemaker-treated men. Am J Med 1982; 73:187-191.
80. Peeters AJ, ten Wolde S, Sedney MI, et al. Heart conduction disturbance: an HLA-B27 associated disease. Ann Rheum Dis 1991; 50:348-350.
81. Bergfeldt L. HLA-B27-associated cardiac disease. Ann Intern Med 1997; 127:621-629.
82. Ribeiro P, Morley KD, Shapiro LM, et al. Left ventricular function in patients with ankylosing spondylitis and Reiter’s disease. Eur Heart J 1984; 5:419-422.
83. Yildirir A, Aksoyek S, Calguneri M, et al. Echocardiographic evidence of cardiac involvement in ankylosing spondylitis. Clin Rheumatol 2002; 21:129-134.
84. Applerouth D, Gottlieb NL. Pulmonary manifestations of ankylosing spondylitis. J Rheumatol 1975; 2:446-453.
85. Rumancik WM, Firooznia H, Davis MS Jr, et al. Fibrobullous disease of the upper lobes: an extraskeletal manifestation of ankylosing spondylitis. J Comput Tomogr 1984; 8(3):225-229.
86. Kiris A, Ozgocmen S, Kocakoc E, Ardicoglu O, Ogur E. Lung findings on high resolution CT in early ankylosing spondylitis. Eur J Radiol 2003; 47(1):71-76.
87. Senocak O, Manisali M, Ozaksoy D, Sevinc C, Akalin E. Lung parenchyma changes in ankylosing spondylitis: demonstration with high resolution CT and correlation with disease duration. Eur J Radiol 2003; 45(2):117-122.
88. Casserly IP, Fenlon HM, Breatnach E, Sant SM. Lung findings on high-resolution computed tomography in idiopathic ankylosing spondylitis—correlation with clinical findings, pulmonary function testing and plain radiography. Br J Rheumatol 1997; 36(6):677-682.
89. El Maghraoui A, Chaouir S, Abid A, et al. Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 2004; 23(2):123-128.
90. Zizzo G, Castriota-Scanderbeg A, Zarrelli N, Nardella G, Daly J, Cammisa M. Pulmonary aspergillosis complicating ankylosing spondylitis. Radiol Med (Torino) 1996; 91(6):817-818.
91. Pontier S, Bigay L, Doussau S, Recco P, Lacassagne L, Didier A. Chronic necrotizing pulmonary aspergillosis and ankylosing spondylarthritis. Rev Mal Respir 2000; 17(3): 683-686.
92. Hendrix WC, Arruda LK, Platts-Mills TA, Haworth CS, Jabour R, Ward GW Jr. Aspergillus epidural abscess and cord compression in a patient with aspergilloma and empyema. Survival and response to high dose systemic amphotericin therapy. Am Rev Respir Dis 1992; 145(6):1483-1486.
93. Hillerdal G. Ankylosing spondylitis lung disease-an underdiagnosed entity? Eur J Respir Dis 1983; 64(6):437-441.
94. Elliott JA, Milne LJ, Cumming D. Chronic necrotising pulmonary aspergillosis treated with itraconazole. Thorax 1989; 44(10):820-821.
95. Stiksa G, Eklundh G, Riebe I, Simonsson BG. Bilateral pulmonary aspergilloma in ankylosing spondylitis treated with transthoracic intracavitary instillations of antifungal agents. Scand J Respir Dis 1976; 57(4):163-170.
96. Massard G, Roeslin N, Wihlm JM, Dumont P, Witz JP, Morand G. Pleuropulmonary aspergilloma: clinical spectrum and results of surgical treatment. Ann Thorac Surg 1992; 54(6):1159-1164.
97. Babatasi G, Massetti M, Chapelier A, et al. Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg 2000; 119(5):906-912.
98. Cerrahoglu L, Unlu Z, Can M, Goktan C, Celik P. Lumbar stiffness but not thoracic radiographic changes relate to alteration of lung function tests in ankylosing spondylitis. Clin Rheumatol 2002; 21(4):275-279.
99. Fisher LR, Cawley MI, Holgate ST. Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis. Ann Rheum Dis 1990; 49:921-925.
100. Seckin U, Bolukbasi N, Gursel G, et al. Relationship between pulmonary function and exercise tolerance in patients with ankylosing spondylitis. Clin Exp Rheumatol 2000; 18(4):503-506.
101. Jones DW, Mansell MA, Samuell CT, Isenberg DA. Renal abnormalities in ankylosing spondylitis. Br J Rheumatol 1987; 26:341-345.
102. Wall BA, Agudelo CA, Pisko EJ. Increased incidence of recurrent hematuria in ankylosing spondylitis: a possible association with IgA nephropathy. Rheumatol Int 1984; 4(1):27-29.
103. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 1998; 17:524-530.
104. Shu KH, Lian JD, Yang YF, et al. Glomerulonephritis in ankylosing spondylitis. Clin Nephrol 1986; 25:169-174.
105. Cruickshank B. Pathology of ankylosing spondylitis. Clin Orthop Relat Res 1971; 74: 43-58.
106. Kovacsovics-Bankowski M, Zufferey P, So AK, Gerster JC. Secondary amyloidosis: a severe complication of ankylosing spondylitis. Two case-reports. Joint Bone Spine 2000; 67:129-133.
107. Gratacos J, Collado A, Sanmarti R, Poch E, Torras A, Munoz-Gomez J. Coincidental amyloid nephropathy and IgA glomerulonephritis in a patient with ankylosing spondylitis. J Rheumatol 1993; 20:1613-1615.
108. Lehtinen K. Ankylosing spondylitis and renal amyloidosis. J Rheumatol 1991; 18:1639.
109. Lance NJ, Curran JJ. Amyloidosis in a case of ankylosing spondylitis with a review of the literature. J Rheumatol 1991; 18(1):100-103.
110. Lai KN, Li PK, Hawkins B, Lai FM. IgA nephropathy associated with ankylosing spondylitis: occurrence in women as well as in men. Ann Rheum Dis 1989; 48:435-437.
111. Krothapalli R, Neeland B, Small S, Duffy WB, Gyorkey F, Senekjian HO. IgA nephropathy in a patient with ankylosing spondylitis and a solitary kidney. Clin Nephrol 1984; 21:134-137.
112. Quinton R, Siersema PD, Michiels JJ, ten Kate FJ. Renal AA amyloidosis in a patient with Bence Jones proteinuria and ankylosing spondylitis. J Clin Pathol 1992; 45:934-936.
113. Browie EA, Glasgow GL. Cauda equina lesions associated with ankylosing spondylitis: a report of three cases. Br Med J 1961; 2:24-27.
114. Hauge T. Chronic rheumatoid arthritis and spondylarthritis associated with neurological symptoms and signs occasionally simulating an intraspinal expansive process. Acta Chir Scand 1961; 120:395-401.
115. Sant SM, O’Connell D. Cauda equina syndrome in ankylosing spondylitis: a case report and review of the literature. Clin Rheumatol 1995; 14(2):224-226.
116. Schroder R, Urbach H, Zierz S. Cauda equina syndrome with multiple lumbar diverticula complicating long-standing ankylosing spondylitis. Clin Invest 1994; 72:1056-1059.
117. Charlesworth CH, Savy LE, Stevens J, Twomey B, Mitchell R. MRI demonstration of arachnoiditis in cauda equina syndrome of ankylosing spondylitis. Neuroradiology 1996; 38:462-465.
118. Bilgen IG, Yunten N, Ustun EE, Oksel F, Gumusdis G. Adhesive arachnoiditis causing cauda equina syndrome in ankylosing spondylitis: CT and MRI demonstration of dural calcification and a dorsal dural diverticulum. Neuroradiology 1999; 41:508-511.
119. Ahn NU, Ahn UM, Nallamshetty L, et al. Cauda equina syndrome in ankylosing spondylitis (the CES-AS syndrome): meta-analysis of outcomes after medical and surgical treatments. J Spinal Disord 2001; 14:427-433.
120. Tapia-Serrano R, Jiminez-Balderas FJ, Murietta S, et al. Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol 1991; 18:841-848.
121. Jiminez-Balderas FJ, Tapia-Serrano R, Madero-Cervera JI, et al. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen treatment. J Rheumatol 1990; 17:497-502.
122. James WH. Might patients with HLA-B27 related diseases benefit from anti-androgenic treatment? (letter). Ann Rheum Dis 1995; 54:531-532.
123. Giltay EJ, Popp-Snijders C, van Denderen JC, van Schaardenburg D, Gooren LJ, Dijkmans BA. Phenylbutazone can spuriously elevate unextracted testosterone assay results in patients with ankylosing spondylitis. J Clin Endocrinol Metab 2000; 85(12): 4923-4924.
124. Spector TD, Ollier W, Perry LA, et al. Free and serum testosteron levels in 276 males: a comparative study of rheumatoid arthritis, ankylosing spondylitis and healthy controls. Clin Rheumatol 1989; 8:37-41.
125. Straub RH, Struharova S, Scholmerich J, Harle P. No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20(6 suppl 28):S52-S59.
126. Rovensky J, Imrich R, Malis F, et al. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2004; 31:2418-2421.
127. van der Paardt M, Dijkmans BAC, Giltay E, van der Horst-Bruinsma IE. Dutch patients with familial and sporadic ankylosing spondylitis do not differ in disease phenotype. J Rheumatol 2002; 29:2583-2584.
128. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondylarthritis early. Ann Rheum Dis 2004; 64:535-543.
129. Laurent MR, Panayi GS. Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis. Ann Rheum Dis 1983; 42:524-528.
130. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999; 26:966-970.
131. Spoorenberg A, Van Der Heijde D, De Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26:980-984.
132. Khan MA. Five classical clinical papers on ankylosing spondylitis. In: Dieppe P, Wolheim FA, Schumacher HR, eds. Classical Papers in Rheumatology. London: Martin Dutz, 2002:118-133.
133. Khan MA. Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Weinblatt ME, Weisman MH, eds. Rheumatology. Vol. 2. Edinburg: Mosby, 2003: 1161-1181.
134. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spon-dylarthropathies among patients with inflammatory bowel disease: a population study. J Rheumatol 2002; 29:511-515.
135. Job-Deslandre C, Menkes CJ. Treatment of juvenile spondylarthropathies with sulpha-salazine. Rev Rheum 1993; 60:489-491.
136. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomised, double blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41: 808-816.
137. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983; 26(2):186-190.
138. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36(7):766-771.
139. Amor B, Santos RS, Nahal R, Listrat V, Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21(10):1883-1887.
140. Claudepierre P, Gueguen A, Ladjouze A, et al. Predictive factors of severity of spondyloarthropathy in North Africa. Br J Rheumatol 1995; 34(12):1139-1145.
141. Brophy S, Mackay K, Al-Saidi A, Taylor G, Calin A. The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 2002; 29(6):1236-1243.
142. Boonen A, Chorus A, Miedema H, et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001; 60(11): 1033-1039.
143. Khan MA, van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990; 16(3):551-579.
144. Arnett FC Jr, Schacter BZ, Hochberg MC, Hsu SH, Bias WB. Homozygosity for HLA-B27. Impact on rheumatic disease expression in two families. Arthritis Rheum 1977; 20(3):797-804.
145. Carter ET, McKenna CH, Brian DD, Kurland LT. Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935-1973. Arthritis Rheum 1979; 22(4):365-370.
146. Radford EP, Doll R, Smith PG. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977; 297(11):572-576.
147. Kaprove RE, Little AH, Graham DC, Rosen PS. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 1980; 23(1):57-61.
148. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J (Clin Res Ed) 1982; 284:449-460.
149. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52(3):174-176.
150. Khan MA, Khan MK, Kushner I. Survival among patients with ankylosing spondylitis: a life-table analysis. J Rheumatol 1981; 8(1):86-90.
151. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995; 8(4):229-241.
152. Melian A, van der Heijde DM, James MK. Etoricoxib in the treatment of ankylosing spondylitis (AS). Arthritis Rheum 2002; 46:S432.
153. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988; 31(9):1111-1116.
154. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38(5):618-627.
155. van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. Treatment ofankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002; 20(6 suppl 28): S67-S70.
156. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313):1187-1193.
157. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18):1349-1356.
158. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48(4): 1126-1136.